A first-in-human phase i study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 Dimesylate), in patients with advanced cancer

Amita Patnaik, Paul Haluska, Anthony W. Tolcher, Charles Erlichman, Kyriakos P. Papadopoulos, Janet L. Lensing, Muralidhar Beeram, Julian R Molina, Drew W. Rasco, Rebecca R. Arcos, Claudia S. Kelly, Sameera R. Wijayawardana, Xuekui Zhang, Louis F. Stancato, Robert Bell, Peipei Shi, Palaniappan Kulanthaivel, Celine Pitou, Lynette B. Mulle, Daphne L. FarringtonEdward M. Chan, Matthew Philip Goetz

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Purpose: p38 MAPK regulates the production of cytokines in the tumor microenvironment and enables cancer cells to survive despite oncogenic stress, radiotherapy, chemotherapy, and targeted therapies. Ralimetinib (LY2228820 dimesylate) is a selective small-molecule inhibitor of p38 MAPK. This phase I study aimed to evaluate the safety and tolerability of ralimetinib, as a single agent and in combination with tamoxifen, when administered orally to patients with advanced cancer. Experimental Design: The study design consisted of a doseescalation phase performed in a 3+3 design (Part A; n = 54), two dose-confirmation phases [Part B at 420 mg (n=18) and Part C at 300 mg (n = 8)], and a tumor-specific expansion phase in combination with tamoxifen for women with hormone receptor- positive metastatic breast cancer refractory to aromatase inhibitors (Part D; n = 9). Ralimetinib was administered orally every 12 hours on days 1 to 14 of a 28-day cycle. Results: Eighty-nine patients received ralimetinib at 11 dose levels (10, 20, 40, 65, 90, 120, 160, 200, 300, 420, and 560 mg). Plasma exposure of ralimetinib (Cmax and AUC) increased in a dose-dependent manner. After a single dose, ralimetinib inhibited p38 MAPK-induced phosphorylation of MAPKAP-K2 in peripheral blood mononuclear cells. The most common adverse events, possibly drug-related, included rash, fatigue, nausea, constipation, pruritus, and vomiting. The recommended phase II dose was 300 mg every 12 hours as monotherapy or in combination with tamoxifen. Although no patients achieved a complete response or partial response,19 patients (21.3%) achieved stable disease with a median duration of 3.7 months, with 9 of these patients on study for ≥ 6 cycles. Conclusions: Ralimetinib demonstrated acceptable safety, tolerability, and pharmacokinetics for patients with advanced cancer.

Original languageEnglish (US)
Pages (from-to)1095-1102
Number of pages8
JournalClinical Cancer Research
Volume22
Issue number5
DOIs
StatePublished - Mar 1 2016

Fingerprint

LY2228820
p38 Mitogen-Activated Protein Kinases
Tamoxifen
Neoplasms
Safety
Aromatase Inhibitors
Tumor Microenvironment
Constipation
Pruritus
Exanthema
Drug-Related Side Effects and Adverse Reactions
Nausea
Area Under Curve
Vomiting
Fatigue
Blood Cells
Research Design
Radiotherapy
Pharmacokinetics
Phosphorylation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A first-in-human phase i study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 Dimesylate), in patients with advanced cancer. / Patnaik, Amita; Haluska, Paul; Tolcher, Anthony W.; Erlichman, Charles; Papadopoulos, Kyriakos P.; Lensing, Janet L.; Beeram, Muralidhar; Molina, Julian R; Rasco, Drew W.; Arcos, Rebecca R.; Kelly, Claudia S.; Wijayawardana, Sameera R.; Zhang, Xuekui; Stancato, Louis F.; Bell, Robert; Shi, Peipei; Kulanthaivel, Palaniappan; Pitou, Celine; Mulle, Lynette B.; Farrington, Daphne L.; Chan, Edward M.; Goetz, Matthew Philip.

In: Clinical Cancer Research, Vol. 22, No. 5, 01.03.2016, p. 1095-1102.

Research output: Contribution to journalArticle

Patnaik, A, Haluska, P, Tolcher, AW, Erlichman, C, Papadopoulos, KP, Lensing, JL, Beeram, M, Molina, JR, Rasco, DW, Arcos, RR, Kelly, CS, Wijayawardana, SR, Zhang, X, Stancato, LF, Bell, R, Shi, P, Kulanthaivel, P, Pitou, C, Mulle, LB, Farrington, DL, Chan, EM & Goetz, MP 2016, 'A first-in-human phase i study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 Dimesylate), in patients with advanced cancer', Clinical Cancer Research, vol. 22, no. 5, pp. 1095-1102. https://doi.org/10.1158/1078-0432.CCR-15-1718
Patnaik, Amita ; Haluska, Paul ; Tolcher, Anthony W. ; Erlichman, Charles ; Papadopoulos, Kyriakos P. ; Lensing, Janet L. ; Beeram, Muralidhar ; Molina, Julian R ; Rasco, Drew W. ; Arcos, Rebecca R. ; Kelly, Claudia S. ; Wijayawardana, Sameera R. ; Zhang, Xuekui ; Stancato, Louis F. ; Bell, Robert ; Shi, Peipei ; Kulanthaivel, Palaniappan ; Pitou, Celine ; Mulle, Lynette B. ; Farrington, Daphne L. ; Chan, Edward M. ; Goetz, Matthew Philip. / A first-in-human phase i study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 Dimesylate), in patients with advanced cancer. In: Clinical Cancer Research. 2016 ; Vol. 22, No. 5. pp. 1095-1102.
@article{0eaa031e4030492980209e63a98877be,
title = "A first-in-human phase i study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 Dimesylate), in patients with advanced cancer",
abstract = "Purpose: p38 MAPK regulates the production of cytokines in the tumor microenvironment and enables cancer cells to survive despite oncogenic stress, radiotherapy, chemotherapy, and targeted therapies. Ralimetinib (LY2228820 dimesylate) is a selective small-molecule inhibitor of p38 MAPK. This phase I study aimed to evaluate the safety and tolerability of ralimetinib, as a single agent and in combination with tamoxifen, when administered orally to patients with advanced cancer. Experimental Design: The study design consisted of a doseescalation phase performed in a 3+3 design (Part A; n = 54), two dose-confirmation phases [Part B at 420 mg (n=18) and Part C at 300 mg (n = 8)], and a tumor-specific expansion phase in combination with tamoxifen for women with hormone receptor- positive metastatic breast cancer refractory to aromatase inhibitors (Part D; n = 9). Ralimetinib was administered orally every 12 hours on days 1 to 14 of a 28-day cycle. Results: Eighty-nine patients received ralimetinib at 11 dose levels (10, 20, 40, 65, 90, 120, 160, 200, 300, 420, and 560 mg). Plasma exposure of ralimetinib (Cmax and AUC) increased in a dose-dependent manner. After a single dose, ralimetinib inhibited p38 MAPK-induced phosphorylation of MAPKAP-K2 in peripheral blood mononuclear cells. The most common adverse events, possibly drug-related, included rash, fatigue, nausea, constipation, pruritus, and vomiting. The recommended phase II dose was 300 mg every 12 hours as monotherapy or in combination with tamoxifen. Although no patients achieved a complete response or partial response,19 patients (21.3{\%}) achieved stable disease with a median duration of 3.7 months, with 9 of these patients on study for ≥ 6 cycles. Conclusions: Ralimetinib demonstrated acceptable safety, tolerability, and pharmacokinetics for patients with advanced cancer.",
author = "Amita Patnaik and Paul Haluska and Tolcher, {Anthony W.} and Charles Erlichman and Papadopoulos, {Kyriakos P.} and Lensing, {Janet L.} and Muralidhar Beeram and Molina, {Julian R} and Rasco, {Drew W.} and Arcos, {Rebecca R.} and Kelly, {Claudia S.} and Wijayawardana, {Sameera R.} and Xuekui Zhang and Stancato, {Louis F.} and Robert Bell and Peipei Shi and Palaniappan Kulanthaivel and Celine Pitou and Mulle, {Lynette B.} and Farrington, {Daphne L.} and Chan, {Edward M.} and Goetz, {Matthew Philip}",
year = "2016",
month = "3",
day = "1",
doi = "10.1158/1078-0432.CCR-15-1718",
language = "English (US)",
volume = "22",
pages = "1095--1102",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - A first-in-human phase i study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 Dimesylate), in patients with advanced cancer

AU - Patnaik, Amita

AU - Haluska, Paul

AU - Tolcher, Anthony W.

AU - Erlichman, Charles

AU - Papadopoulos, Kyriakos P.

AU - Lensing, Janet L.

AU - Beeram, Muralidhar

AU - Molina, Julian R

AU - Rasco, Drew W.

AU - Arcos, Rebecca R.

AU - Kelly, Claudia S.

AU - Wijayawardana, Sameera R.

AU - Zhang, Xuekui

AU - Stancato, Louis F.

AU - Bell, Robert

AU - Shi, Peipei

AU - Kulanthaivel, Palaniappan

AU - Pitou, Celine

AU - Mulle, Lynette B.

AU - Farrington, Daphne L.

AU - Chan, Edward M.

AU - Goetz, Matthew Philip

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Purpose: p38 MAPK regulates the production of cytokines in the tumor microenvironment and enables cancer cells to survive despite oncogenic stress, radiotherapy, chemotherapy, and targeted therapies. Ralimetinib (LY2228820 dimesylate) is a selective small-molecule inhibitor of p38 MAPK. This phase I study aimed to evaluate the safety and tolerability of ralimetinib, as a single agent and in combination with tamoxifen, when administered orally to patients with advanced cancer. Experimental Design: The study design consisted of a doseescalation phase performed in a 3+3 design (Part A; n = 54), two dose-confirmation phases [Part B at 420 mg (n=18) and Part C at 300 mg (n = 8)], and a tumor-specific expansion phase in combination with tamoxifen for women with hormone receptor- positive metastatic breast cancer refractory to aromatase inhibitors (Part D; n = 9). Ralimetinib was administered orally every 12 hours on days 1 to 14 of a 28-day cycle. Results: Eighty-nine patients received ralimetinib at 11 dose levels (10, 20, 40, 65, 90, 120, 160, 200, 300, 420, and 560 mg). Plasma exposure of ralimetinib (Cmax and AUC) increased in a dose-dependent manner. After a single dose, ralimetinib inhibited p38 MAPK-induced phosphorylation of MAPKAP-K2 in peripheral blood mononuclear cells. The most common adverse events, possibly drug-related, included rash, fatigue, nausea, constipation, pruritus, and vomiting. The recommended phase II dose was 300 mg every 12 hours as monotherapy or in combination with tamoxifen. Although no patients achieved a complete response or partial response,19 patients (21.3%) achieved stable disease with a median duration of 3.7 months, with 9 of these patients on study for ≥ 6 cycles. Conclusions: Ralimetinib demonstrated acceptable safety, tolerability, and pharmacokinetics for patients with advanced cancer.

AB - Purpose: p38 MAPK regulates the production of cytokines in the tumor microenvironment and enables cancer cells to survive despite oncogenic stress, radiotherapy, chemotherapy, and targeted therapies. Ralimetinib (LY2228820 dimesylate) is a selective small-molecule inhibitor of p38 MAPK. This phase I study aimed to evaluate the safety and tolerability of ralimetinib, as a single agent and in combination with tamoxifen, when administered orally to patients with advanced cancer. Experimental Design: The study design consisted of a doseescalation phase performed in a 3+3 design (Part A; n = 54), two dose-confirmation phases [Part B at 420 mg (n=18) and Part C at 300 mg (n = 8)], and a tumor-specific expansion phase in combination with tamoxifen for women with hormone receptor- positive metastatic breast cancer refractory to aromatase inhibitors (Part D; n = 9). Ralimetinib was administered orally every 12 hours on days 1 to 14 of a 28-day cycle. Results: Eighty-nine patients received ralimetinib at 11 dose levels (10, 20, 40, 65, 90, 120, 160, 200, 300, 420, and 560 mg). Plasma exposure of ralimetinib (Cmax and AUC) increased in a dose-dependent manner. After a single dose, ralimetinib inhibited p38 MAPK-induced phosphorylation of MAPKAP-K2 in peripheral blood mononuclear cells. The most common adverse events, possibly drug-related, included rash, fatigue, nausea, constipation, pruritus, and vomiting. The recommended phase II dose was 300 mg every 12 hours as monotherapy or in combination with tamoxifen. Although no patients achieved a complete response or partial response,19 patients (21.3%) achieved stable disease with a median duration of 3.7 months, with 9 of these patients on study for ≥ 6 cycles. Conclusions: Ralimetinib demonstrated acceptable safety, tolerability, and pharmacokinetics for patients with advanced cancer.

UR - http://www.scopus.com/inward/record.url?scp=84962283275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962283275&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-15-1718

DO - 10.1158/1078-0432.CCR-15-1718

M3 - Article

C2 - 26581242

AN - SCOPUS:84962283275

VL - 22

SP - 1095

EP - 1102

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -